Eli Lilly increases its supply chain layout in China, the Hong Kong Innovative Drugs ETF (159567) rises nearly 1%, institutions are optimistic about the long-term allocation value of the sector

On March 12th, the Hong Kong stock market saw active trading in the innovative drug sector, with the Hong Kong Innovative Drug ETF (159567) rising by 0.95%, and the trading volume exceeding 166 million yuan. Component stocks such as KEYMED BIO-B and Ascentage Pharma-B also experienced gains. Eli Lilly announced plans to invest $3 billion in China over the next decade to expand supply chain capacity, particularly in the production of oral solid dosage forms. Dongxing Securities is optimistic about the medium to long-term allocation value of the innovative drug sector, believing that short-term stock price fluctuations do not change the long-term growth logic of the industry